AZNAcerta Pharma BVRunning, no new patients
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
Diffuse Large B-Cell Lymphoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 611 (final count)
- Started
- Oct 8, 2020
- Main results expected
- Feb 22, 2027
- Fully finished
- Feb 22, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free survival (PFS) per the Lugano Classification for NHL in Arm A compared to Arm B
Measured over: at every single visit up to 60 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04529772 · record last updated 2026-10-13 · checked 2026-11-09 15:47 UTC